Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 16, 2026
Can you apply?
This grant is for multidisciplinary research teams pursuing innovative approaches to develop hepatitis B cures specifically in persons co-infected with HIV and HBV. Eligible applicants typically include nonprofit research institutions, universities, hospitals, and medical research organizations with NIH funding capability. Applicants must demonstrate institutional support, scientific rigor, and a clear multidisciplinary research plan. The scope is national and international. Funded research activities include basic science, translational, and clinical research aimed at advancing hepatitis B cure strategies in co-infected populations, with particular emphasis on collaborative, cross-disciplinary approaches involving virology, immunology, hepatology, and related fields.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Jun 27, 2025 Applications open
- Aug 19, 2026 Application deadline in 33 days
- Mar 1, 2027 Award announced
- Mar 1, 2027 Project start
Program description
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by soliciting applications to support Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV (PLWH) and Hepatitis B Virus (HBV). This program will focus on: elucidating mechanisms of persistence and pathogenesis; discovering and developing clinically relevant biomarkers; discovering and/or validating host and/or new viral drug targets; and developing non-invasive diagnostics. Each MRA-HBV award will support an observational cohort paired with a multi-disciplinary teams focused on research that leverages samples from existing clinical data and sample repositories from previous cohort studies. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- County Government
- Hospital
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
How to apply
Application links
Key dates & requirements
Required documents
- NIH Form SF-424 (R&R) and associated forms (SF-424 Supp-11-01, Research and Related Personal Data)
- Project narrative and specific aims (typically 12-15 pages)
- Research strategy section including background, significance, innovation, approach, and timeline
- Detailed budget justification and budget narrative
- Institutional biosketches for all key personnel
- Letters of support from collaborating institutions and co-investigators
- Evidence of IRB or IACUC approval (if human or animal subjects involved)
- Facilities and equipment description
- Data management and sharing plan
- Authentication of key biological/chemical resources
Program contact
- 👤 Josh Radke, Ph.D. National Institute of Allergy and Infectious Disease (NIAID)
- 📧 josh.radke@nih.gov
- 📞 301-761-6525
Funding track record
Recent awards under CFDA 93.855 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$246,626,852
-
$201,437,825
-
$185,816,804
-
$180,737,624
-
$136,265,880
-
$116,817,868
-
$93,394,862
-
$89,845,851
-
$74,456,241
-
$72,987,380
Top States by Funding
- CA 8 awards $696.2M
- MA 6 awards $602.8M
- NY 6 awards $335.0M
- TX 3 awards $280.9M
- GA 5 awards $257.9M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.855). How funding has trended year over year.
| 2024 | $4,073,812,529 | |
| 2025 | $4,378,235,639 | |
| 2026 est. | $4,299,426,996 |
FAQ
Who can apply for this grant?
Research institutions, universities, medical centers, and nonprofits with demonstrated NIH grant management capability can apply. Individual researchers typically apply through their institution.
What types of research are supported?
Multidisciplinary research including basic science, translational research, and clinical studies focused on hepatitis B cure in persons co-infected with HIV. Collaborative, team-based approaches are strongly encouraged.
What is the typical funding range?
NIH research project grants typically range from $150,000 to over $2 million per year depending on research scope. Consult the specific funding opportunity announcement (FOA) for details.
What makes a competitive application?
Strong applications demonstrate scientific innovation, clearly articulated research questions, feasibility, team multidisciplinarity, institutional support, and potential impact on hepatitis B cure development for this vulnerable population.
When is the application deadline?
The application opens June 27, 2025. Consult the NIH website or specific FOA for submission deadline dates, which typically fall 30-60 days after the open date.
💡 Tips for applicants
- Prioritize multidisciplinary team composition: Include researchers from complementary fields (virology, immunology, clinical medicine) and demonstrate clear collaboration and communication plans. Reviewers strongly favor integrated teams over siloed contributions.
- Focus on hepatitis B cure mechanisms: Emphasize novel, high-impact approaches to hepatitis B eradication or functional cure rather than incremental improvements. Clearly articulate why your approach is transformative for HIV/HBV co-infected persons.
- Address co-infection complexity: Explain how HIV co-infection complicates HBV cure and how your research specifically accounts for the unique immunological and viral dynamics of this population.
- Leverage preliminary data: Present compelling pilot data demonstrating feasibility and promising early results. NIH reviewers view strong preliminary findings as critical for funding competitiveness.
- Detail institutional resources: Clearly document access to clinical cohorts, laboratory facilities, biobanks, and specialized equipment essential for your research. Demonstrate strong institutional commitment through cost-sharing or dedicated resources.
⚠️ Common mistakes
Applications often fail by proposing isolated single-discipline research that lacks true multidisciplinary integration, or by failing to address the unique challenges of HIV/HBV co-infection specifically. Applicants frequently underestimate the complexity of co-infected immunology and propose approaches designed for HBV mono-infected persons. Additionally, weak preliminary data or insufficient evidence of team collaboration and previous success working together significantly weakens competitiveness.
Similar grants
- OPEN Centers for AIDS Research (CFAR) — National Institutes of Health
- OPEN HIV/AIDS Clinical Trials Network Leadership and Operations Centers — National Institutes of Health
- OPEN HIV/AIDS Clinical Trials Network Laboratory Centers — National Institutes of Health
- CLOSED Infectious Diseases Clinical Trials Network (IDCTN) — National Institutes of Health
- OPEN Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria – A Model for Mosquito-Borne Diseases — National Institutes of Health